Health

LILYSILK Continues Partnership with National Breast Cancer Foundation for Breast Cancer Awareness Month

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- LILYSILK , the world's leading silk brand with a mission to inspire people to live better, sustainable lives, proudly continues its collaboration withNational Breast Canc...

2024-10-29 22:00 1121

Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis

Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks sof...

2024-10-29 21:00 1014

DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation

SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension,HyperQure uses a laparoscopic approach t...

2024-10-29 21:00 1445

Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.

CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective onOctober 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of ...

2024-10-29 20:00 1813

GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies

YONGIN, South Korea, Oct. 28, 2024 /PRNewswire/ -- GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy (GA...

2024-10-29 09:13 1644

KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I

Clinical Trials at American Society of Nephrology (ASN) – Kidney Week 2024 SAN FRANCISCO, Oct. 28, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to...

2024-10-29 05:42 983

Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth

MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry  has raised an oversubscribed US$18m A2 financing round to commercialise its wearable gut health monitoring device, capitalizing on increased adoption by a growing cohort of US hospitals. This adoption is driven by Alimetr...

2024-10-29 05:08 1084

$3M GRANT TO ACCELERATE DEVELOPMENT OF NEUROPLASTOGENS FOR SUBSTANCE USE DISORDER TREATMENT

CRC-P GRANT SECURED BY TESSARA THERAPEUTICS, PSYLO, AND THE UNIVERSITY OF SYDNEY TO ADVANCE BRAIN-REWIRING TREATMENTS FOR ADDICTION BOULDER, Colo. , Oct. 28, 2024 /PRNewswire/ -- Tessara Therapeutics Psylo , and the...

2024-10-29 02:00 1431

Ping An Health Collaborates with Industry to Launch China's First "Internet-Based Family Doctor Service Standards"

HONG KONG and SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently participated in the finalization meeting for the "High-Quality Development Standards for Internet-Based...

2024-10-28 21:30 2077

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

* Revenue Reached RMB10,461 Million in the Third Quarter, Excluding COVID-19 Commercial Projects, Up 14.6% Year-over-Year * Revenue Reached RMB27,702 Million for the First Three Quarters, Excluding COVID-19 Commercial Projects, Up 4.6% Year-over-Year * Net Profit Attributable to the Owners o...

2024-10-28 19:03 1848

I-Mab to Participate at the Truist Securities BioPharma Symposium

ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meet...

2024-10-28 19:00 893

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expressio...

2024-10-28 17:00 1006

RiboX Therapeutics Announces FDA Clearance for IND Application of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation

PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration (FDA) has cleared its IND application for th...

2024-10-26 01:24 3906

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Fo...

2024-10-26 00:33 1670

Lifezoom Unveils Next-Gen 3-in-1 Handheld Red Light Therapy Wand - Transform Your Skincare Routine

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Lifezoom, a new force in red light therapy with strong R&D capabilities, is about to launch its handheld red light therapy wand, its newest device, as a declaration of its high-end brand route and also shows its determination of providing users with safer a...

2024-10-25 21:00 1045

WOORIEN launches 'MyVet CT Plus': Advanced Veterinary imaging Solution

* Lowering CT barriers and improving diagnostic quality * Spiral-Linear Technology with Enhanced Power * Various and Wide FOV with Reduced Scan Time HWASEONG, South Korea, Oct. 25, 2024 /PRNewswire/ -- WOORIEN Co., Ltd, a company specializing in veterinary imaging equipment and solutions, pr...

2024-10-25 21:00 2426

MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia

SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 inAustralia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycoba...

2024-10-25 19:29 1293

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone ...

2024-10-25 15:14 1125

SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...

2024-10-24 20:00 825

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...

2024-10-24 20:00 1133
12345678 ... 280